Published in Biochem Biophys Res Commun on July 24, 2010
Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases. Cell Cycle (2011) 1.24
Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites. Neurobiol Aging (2012) 1.01
Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy (2014) 0.99
Function of the master energy regulator adenosine monophosphate-activated protein kinase in stroke. J Neurosci Res (2013) 0.88
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. J Med Chem (2014) 0.84
AMP-Activated Protein Kinase (AMPK) and Energy-Sensing in the Brain. Exp Neurobiol (2012) 0.84
Insulin Resistance Prevents AMPK-induced Tau Dephosphorylation through Akt-mediated Increase in AMPKSer-485 Phosphorylation. J Biol Chem (2015) 0.83
Activation of mTOR: a culprit of Alzheimer's disease? Neuropsychiatr Dis Treat (2015) 0.83
AMPK activation--protean potential for boosting healthspan. Age (Dordr) (2013) 0.78
Glucose regulates amyloid β production via AMPK. J Neural Transm (Vienna) (2015) 0.76
AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep (2016) 0.75
Adaptive and regulatory mechanisms in aged rats with postoperative cognitive dysfunction. Neural Regen Res (2014) 0.75
Letter to the Editor on "Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis". Biochem Biophys Res Commun (2010) 0.75
Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism. Front Endocrinol (Lausanne) (2017) 0.75
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA (2006) 72.59
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol (2007) 15.30
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A (1998) 4.49
The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest (2003) 4.11
Cholesterol, lipid rafts, and disease. J Clin Invest (2002) 4.05
AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol (2007) 3.72
AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci (2001) 2.51
Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem (2003) 1.73
The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett (2001) 1.49
AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) (2006) 1.49
Characterisation of 5'-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5'-AMP analogues on enzyme activity. Biochem Biophys Res Commun (1994) 1.37
Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem (2008) 1.34
AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res (2009) 1.23
Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts. Nat Clin Pract Neurol (2007) 1.06
Endotoxin-induced alterations of lipid and fatty acid compositions in rat liver peroxisomes. J Endotoxin Res (2000) 1.03
A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. J Cell Biol (2004) 1.02
Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J Neurochem (2008) 0.99
Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. Neurosci Lett (2008) 0.93
Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 3.95
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem (2005) 2.57
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci (2004) 1.89
Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol (2009) 1.83
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol (2008) 1.54
5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol (2005) 1.49
AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) (2006) 1.49
Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J Neuroinflammation (2009) 1.42
N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res (2004) 1.38
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer (2007) 1.31
Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res (2004) 1.29
S-Nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke. J Cereb Blood Flow Metab (2005) 1.28
T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology (2006) 1.25
Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int (2006) 1.24
Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. Nitric Oxide (2006) 1.22
Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol (2004) 1.22
Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis (2003) 1.17
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol (2006) 1.17
GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia (2007) 1.14
A study on methane and nitrous oxide emissions characteristics from anthracite circulating fluidized bed power plant in Korea. ScientificWorldJournal (2012) 1.13
Sphingolipid signaling and redox regulation. Free Radic Biol Med (2006) 1.12
HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J (2005) 1.11
Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. J Neurochem (2003) 1.11
Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem (2007) 1.11
Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res (2005) 1.09
S-nitrosoglutathione a physiologic nitric oxide carrier attenuates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol (2010) 1.09
Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res (2004) 1.09
Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. Biochem J (2008) 1.08
Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine. Exp Neurol (2007) 1.08
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res (2006) 1.06
The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J Neurochem (2008) 1.05
Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res (2006) 1.04
N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. Brain Res (2003) 1.03
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol (2006) 1.03
Caffeic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia. J Neurochem (2007) 1.03
High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor kappaB and AP-1 activities. J Endocrinol (2008) 1.03
Peroxisomal participation in psychosine-mediated toxicity: implications for Krabbe's disease. J Neurosci Res (2005) 1.02
Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J (2002) 1.02
Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine. Neurosci Lett (2002) 1.02
Dysfunction of peroxisomes in twitcher mice brain: a possible mechanism of psychosine-induced disease. Biochem Biophys Res Commun (2006) 1.01
Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett (2002) 0.99
Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation (2006) 0.99
Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J Neurochem (2008) 0.99
Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med (2004) 0.99
The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke. J Neurochem (2012) 0.98
A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: implications for neuroinflammatory diseases. J Neurosci (2004) 0.98
Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem (2008) 0.98
Development of Korean standard brain templates. J Korean Med Sci (2005) 0.97
Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol (2008) 0.97
Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem (2011) 0.97
Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia (2010) 0.96
Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol (2011) 0.95
S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats. J Neuroinflammation (2011) 0.95
Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun (2009) 0.95
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm (2004) 0.95
Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat. J Neuroinflammation (2009) 0.94